Can Parkinson's disease be fatal? Is it curable?

Patients with Parkinson's disease often experience psychological issues such as depression and anxiety; psychological counseling and support can help them cope with the mental stress caused by the disease. Summary The treatment of Parkinson's disease requires a comprehensive approach integrating medication, surgery, rehabilitation, and psychological counseling—tailored flexibly to each patient’s specific condition and symptom profile to achieve optimal therapeutic outcomes. With advances in regenerative medicine, stem cell therapy for Parkinson’s disease (PD) has made significant progress in recent years, offering new hope for this chronic neurodegenerative disorder. Regarding the real-world efficacy of stem cell therapy in PD patients, several latest clinical cases and research updates are available for reference: In January 2024, Sizhou Biomedical Co., Ltd. and Shanghai East Hospital jointly launched a clinical study titled “Clinical-Grade iPSC-Derived Dopaminergic Neural Progenitor Cell Therapy for Moderate-to-Severe Parkinson’s Disease,” which received formal approval from China’s National Health Commission and National Medical Products Administration. It is reported to be the first clinical-grade iPSC-derived cell transplantation therapy for Parkinson’s disease in China—and the first autologous iPSC-derived cell replacement therapy for PD in China and the second globally. ・The first participant, after receiving the clinical-grade iPSC-derived cell transplant, experienced no surgical or perioperative complications or other adverse safety events; ・All laboratory test indicators remained normal; the patient was discharged smoothly and has since completed the observation period and entered the formal follow-up phase. On April 19, 2024, Aspen Neuroscience initiated an ASPIRO Phase 1/2a clinical trial (NCT06344026) in the United States. ANPD001 is Aspen Neuroscience’s investigational stem cell therapy designed to replace neurons lost due to the disease. The study assessed the safety and tolerability of ANPD001 in up to nine adults aged 50–70 with moderate-to-severe Parkinson’s disease. Dosing began in April, supported by an $8 million grant from the California Institute for Regenerative Medicine to Aspen. ・In the Phase 1/2a clinical trial of ANPD001, the first cohort of PD patients completed dosing and demonstrated reasonable safety. ・Three adult participants underwent two consecutive, escalating-dose direct brain injections under general anesthesia. Within one to three months post-procedure, none developed serious complications, nor did any experience severe intraoperative bleeding. On May 10, 2024, a clinical study led by Prof. Renzhi Wang and Prof. Xinjie Bao from the Department of Neurosurgery, and Prof. Xinhua Wan from the Department of Neurology at Peking Union Medical College Hospital—entitled “Phase I Study on the Safety and Preliminary Efficacy of Intranasal Transplantation of Human Neural Stem Cells in Parkinson’s Disease (ANGE-S003)”—was published in the international journal Journal of Neurology, Neurosurgery & Psychiatry. The study had been underway since five years prior and enrolled 18 patients with mid-to-late-stage Parkinson’s disease who had been living with the condition for over five years.

How should we view Anthropic?

This month, the AI sector has truly taken a beating—so much so that I felt numb. This morning, I chatted with a friend. I warned: Right now, we must remain highly vigilant about valuation risks associated with leading closed-source large models. My friend asked for the core rationale—so here’s the breakdown. In summary: The long-term industrial growth logic for large models remains intact, but the bubble in the private equity market has reached the eve of correction. I. Anthropic’s frenetic lobbying efforts in Congress By 2026, the company’s policy-related activities have become unusually intense—just consider how anxious they appear: 1. February: Released an official report accusing MiniMax, DeepSeek, and Moonshot of deploying 24,000 fake accounts to make over 16 million calls to Claude’s API—labeling it “malicious distillation” (Source: Anthropic official report, February 2026); 2. April: Established a dedicated political action committee, AnthroPAC, and hired Ballard Partners—a lobbying firm deeply tied to the Trump camp—to forge connections within U.S. politics (Source: Public financial reporting, April 2026); 3. June 10: Formally wrote to the Senate Banking Committee, accusing Alibaba’s Tongyi Qwen of registering 25,000 fraudulent accounts over two months and initiating 28.8 million model interactions—calling it “the largest-scale distillation attack in history.” The letter was simultaneously copied to the White House and key senators and representatives in both chambers (Sources: Reuters, CNBC, Bloomberg—original letter obtained); 4. June 12: In a dramatic reversal, the U.S. Department of Commerce added Anthropic’s flagship models Fable 5 and Mythos 5 to its export control list, forcing the company to withdraw its most powerful models globally (Source: Financial Times deep-dive report, June 2026); 5. July 16: Publicly named Zhipu AI for alleged model distillation; on the same day, the company’s head of security stated at the Aspen Security Forum that its platform bans millions of violative API accounts weekly; 6. Mid-July: CEO Dario Amodei testified before Congress, making the outlandish claim that Kimi K3 had stolen an internal pre-research model that Anthropic had never opened to the public—no API, no weights, no sample outputs ever released. When challenged by a senator about logical inconsistencies, Amodei resorted to coining the term “future model leakage” to deflect; 7. July 21: Donated an additional $20 million to the policy group Public First Action, bringing its total investment to $40 million—explicitly earmarked on its official website to advance chip-and-equipment export controls and suppress competing models’ distillation efforts (Source: Anthropic official announcement, July 21, 2026); 8. July 22: The White House’s Chief Technology Officer echoed the accusations against K3 on X (formerly Twitter), yet still has not produced a complete technical verification report. Two critical contextual developments accompany these events: 1. Congress is concurrently advancing the “U.S. AI Model Theft Prevention Act” and amendments to the National Defense Authorization Act (NDAA), aiming to establish corporate sanctions blacklists specifically for “model distillation”; 2. Anthropic filed its IPO S-1 registration statement; even OpenAI President Greg Brockman publicly distanced himself from this narrative, stating plainly: “The K3 model is exceptionally capable—declaring distillation at this stage is premature” (Sources: U.S. Congressional public documents; overseas media reports from April–July 2026).

Aspen Neuroscience, Bambusa Therapeutics launch US IPOs as biotech boom rolls on

17 hours ago

Aspen Neuroscience and Bambusa Therapeutics launched US IPO roadshows, adding to a biotech sector wave despite rising borrowing costs. Both firms are developing early-stage therapies for neurodegenerative and inflammatory diseases, with share prices set between $15 and $17.

reuters

2026-10-26

Aspen Neuroscience, Bambusa Therapeutics launch US IPOs as biotech boom rolls on

Aspen Neuroscience, Bambusa Therapeutics launch US IPOs as biotech boom rolls on

FAQ